Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 YearsThe Motley Fool • 09/30/25
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TranscriptSeeking Alpha • 09/18/25
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025GlobeNewsWire • 09/17/25
Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/YZacks Investment Research • 08/05/25
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/04/25
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/28/25
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS PipelineGlobeNewsWire • 07/21/25
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4GlobeNewsWire • 07/09/25
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21GlobeNewsWire • 07/07/25
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness MonthGlobeNewsWire • 06/20/25
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025GlobeNewsWire • 06/11/25
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.GlobeNewsWire • 05/27/25